Genetic control of chemokines in severe human internal carotid artery stenosis by G. Ghilardi et al.
www.elsevier.com/locate/issn/10434666
Cytokine 41 (2008) 24–28Genetic control of chemokines in severe human
internal carotid artery stenosis
Giorgio Ghilardi a,*, Maria Luisa Biondi b, Olivia Turri b, Francesca Pateri b,
Gianvico Melzi d’Eril a,b, Roberto Scorza a
a Dipartimento MCO, Universita` degli Studi di Milano, Via A. Di Rudinı`, 8, I-20142 Milano, Italy
b Laboratorio di Chimica Clinica e Microbiologia, Ospedale S. Paolo, Via A. Di Rudinı`, 8, I-20142 Milano, Italy
Received 20 October 2006; received in revised form 5 July 2007; accepted 16 October 2007Abstract
Background and purpose: Atherosclerosis is an inﬂammatory disease. Chemokines and chemokine receptors are known to be involved
in atherogenesis. Common single nucleotide polymorphisms (SNPs) aﬀect transcription in response to inﬂammatory stimuli. The aim of
this study was to evaluate the correlations between MCP-1, RANTES, SDF-1, CCR2, and CCR5 gene polymorphisms with increased
risk of internal carotid artery (ICA) stenosis. Methods: Hundred and twelve patients, consecutively recruited for ICA occlusive disease,
and 282 controls were genotyped for MCP-1-2518G, RANTES-403A, CCR5D32, CCR2 V64I, and SDF-1-801A polymorphisms.
Results: The frequency of the SDF-1A allele was signiﬁcantly diﬀerent between cases and controls: 0.32 vs. 0.20, respectively (OR
1.81; 95% CI 1.25–2.60; p = 0.007). The frequency of the RANTES-403G allele was signiﬁcantly higher in patients with stenosis
>70% (OR, 2.45; 95% CI 1.12–5.71; p = 0.015). No signiﬁcant diﬀerences were observed with the other polymorphisms. Conclusion:
The reported results seem to correlate the polymorphisms of the genes encoding for SDF-1, RANTES with pathogenesis and progression
of ICA occlusive disease. Although suggestive, these results need conﬁrmation in prospective cross-sectional studies.
 2007 Elsevier Ltd. All rights reserved.
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Arteriosclerosis is a multi-factorial condition which is
determined both by environmental and genetic factors,
involving a strong inﬂammatory component [1,2]. Athero-
genesis requires a complex interplay between mononuclear
cells, endothelial cells, vascular smooth muscle cells,
growth factors, and cytokines [3]. The formation of athero-
sclerotic lesions proceeds through a sequence from fatty
streak to ﬁbrofatty matrix and ﬁbrous plaque. Monocyte
arrest on vascular endothelial lining is not only considered
to be an initial step, but appears to play a causative role in
the ensuing pathological process [4]. The mechanisms by1043-4666/$ - see front matter  2007 Elsevier Ltd. All rights reserved.
doi:10.1016/j.cyto.2007.10.007
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E-mail address: giorgio.ghilardi@unimi.it (G. Ghilardi).which monocytes arrest on the luminal surface of vessels
prone to form artherosclerotic lesion are incompletely
understood. Chemokines are a superfamily of structurally
related small chemotactic cytokines involved in leukocyte
traﬃcking and activation. Binding of chemokines to their
receptors elicits a variety of cellular responses including
an increas in intracellular free calcium concentration, inte-
grin activation, and leukocyte migration [5].
The Regulated uponActivationNormal T-cell Expressed
and Secreted (RANTES), monocyte chemoattractant pro-
tein-1 (MCP-1), and stromal cell-derived factor 1b (SDF-
1b) chemokines have been implicated in atherogenesis [6–
8]. RANTES is a potent chemoattractant for monocytes,
lymphocytes, eosinophilis, and basophilis [9]. RANTES
interacts with the chemokine receptors CCR1, CCR3, and
CCR5, and has been implicated in cardiac inﬂammatory dis-
order after organ transplantation [10,11]. Systemic blockage
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macrophage inﬁltration in carotid arteries of ApoE/
mice [11].
MCP-1 has been implicated in the recruitment of mono-
cytes into early atherosclerotic lesions, the development of
intima hyperplasia after angioplasty, vasculogenesis and
thrombosis [12,13].
SDF-1 is a potent platelet agonist implicated in lympho-
cyte arrest on inﬂamed endothelium [14].
Genetic variations commonly occur in the regulatory
regions of chemokine genes: such polymorphisms aﬀect
chemokine gene transcription in response to inﬂammatory
stimuli, most likely by modulating leucocyte recruitment
and activation in inﬂammation foci [15].
Internal carotid artery (ICA) occlusive disease has been
recognized as a major cause of stroke. Carotid endarterec-
tomy has been validated by several large trials as eﬀective
in prevention of stroke secondary to severe ICA stenosis
[16–19].
Rupture of atherosclerotic plaques is crucial in the path-
ogenesis of acute coronary syndromes and strokes [20,21].
Interactions, within the ICA stenosing plaque, between
connective tissue and the cells embedded into the ﬁbrous
cap overlying the inner core appear to determine the his-
tory of the ICA stenosis: plaque rupture or ulceration,
intraplaque haemorrhage and luminal thrombosis are rec-
ognized causes of stroke [20,21]. Speciﬁc markers to iden-
tify in vivo ruptured plaques, or plaques prone to rupture,
are not available.
The aim of this study was to investigate whether RAN-
TES, MCP-1, SDF-1, CCR2, and CCR5 polymorphisms
are associated with the presence of severe ICA occlusive
disease and/or are involved in plaque stability in humans.
2. Subjects and methods
We studied 112 subjects aﬀected with ICA occlusive dis-
ease consecutively referred to our vascular surgery unit and
282 unselected volunteer outpatients (controls) consecu-
tively referred to our vascular ultrasound laboratory, with
no evidence of ICA occlusive disease upon ultrasound col-
our Doppler (USCD) examination. Informed consent was
obtained.
All 394 subjects underwent vascular evaluation, includ-
ing history, clinical examination, thorough USCD of the
accessible arterial tree, and ECG at rest. Within the
patients group, 35% were found to be aﬀected with coro-
nary artery disease, 2% with peripheral arterial occlusive
disease and 2% with abdominal aortic aneurysm. There
was no relevant atherosclerotic ﬁnding in the control
group. Patients underwent additional neurological evalua-
tion and cerebral CT to assess symptoms and/or cerebral
infarction related to ICA stenosis.
Hypertension was deﬁned according to the 7th JNC
Report on hypertension [22].
Smoker deﬁnition included both ex-smokers and active
smokers.Hypercholesterolemia was deﬁned as total serum choles-
terol levels >200 mg/dL.
Carotid stenosis was assessed by USCD and conﬁrmed
by multidetector helical angio-CT (MHACT). In this
paper, the degree of stenosis is reported in percentages
equivalent to the NASCET deﬁnition [23,24].
According to the AHA criteria [25], some 87 patients
with >50% symptomatic stenosis and >70% asymptomatic
stenosis underwent eversion endarterectomy and 25 asymp-
tomatic subjects were not operated upon. 82 plaques were
inspected in the operating room by a pathologist and mac-
roscopic observations were recorded in the operation
report ﬁle. Carotid plaques were classiﬁed according to
the AHA statement [26]. For the purpose of this paper, pla-
ques were also deﬁned as soft or hard, according to the rel-
ative content of lipids, debris or intraplaque haemorrhage,
and calcium. The macroscopic examination was then
matched to the preoperative MHACT examination and a
substantial agreement was found in any instance. Given
the ability of MHACT to accurately estimate the calcium
content of the plaque [27], a cut-oﬀ of 33% calcium content
was established to deﬁne soft plaques (<33% calcium con-
tent) and hard plaques (>33% calcium content). Patients
with bilateral lesions were considered only once in this
study (ﬁrst operation).
Whole blood from patients and controls was collected
into potassium EDTA. DNA was prepared with commer-
cial extraction kits. The PCR reaction for MCP-1, RAN-
TES, CCR5, CCR2, SDF-1 was carried out as described
elsewhere [28].
Diﬀerences between groups were examined by v2 tests.
Odds ratios were calculated as an index of the association
of the diﬀerent genotypes with each phenotype. For each
odds ratio, 2-tailed probability values and 95% conﬁdence
intervals were calculated.
Multiple logistic regression analysis was used to calcu-
late the odds ratio of ICA stenosis and its 95% CI in sub-
jects exposed to speciﬁc risk factors. Only the factors which
were signiﬁcantly associated with the development of caro-
tid plaque on univariate analysis were included in the logis-
tic regression analysis.
All statistical analyses were two-sided and were per-
formed with Stata Statistical Software (Stata Corporation,
College Station, TX).
Statistical analysis was assumed signiﬁcant for a proba-
bility value of <0.05.3. Results
Allele frequencies in both control and patient popula-
tions were within Hardy Weinberg equilibrium.
Gender frequency was similar between the two groups
(p = 0.71); controls were slightly younger (mean ages:
patients 68 ± 6 yrs. controls 65 ± 7: p = 0.02) (Table 1).
The adjusted odds ratios associated with the presence of
the G/A SDF-1 genotype (G/A + AA versus GG) and A
Table 1
General characteristics and selected risk factors for carotid artery occlusive disease
Patients (n = 112) (%) Controls (n = 282) (%) OR (95%CI) p
Age 68 ± 6 65 ± 7 0.02
Men: women 75/:37 184:98 1.07 (0.66–1.77) 0.74
Hypertension 70/110 64 100/278 36 3.11(1.92–5.07) 0.0001
Cigarette smoking 84/112 75 124/275 45 3.65(2.18–6.18) 0.0001
Diabetes mellitus 25/108 23 44/275 16 1.58(0.86–2.82) 0.10
Hypercholesterolemia 82/105 78 179/275 65 1.91(1.10–3.38) 0.014
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(95% CI, 1.25–2.60; p = 0.0007), respectively (Table 2).
No diﬀerences were noted in-2518A/GMCP-1, -403G/A
RANTES, CCR5D32 and CCR2 V64I variants distribution
compared to controls (Table 2).
Twenty patients had had TIA, 32 had had strokes or
silent cerebral infarction and 60 were asymptomatic. No
diﬀerences in clinical signs and symptoms (e.g.: transient
ischemic attacks and stroke or silent cerebral infarction)
were found in correlation with the ﬁve genotypes.
In patients, -403G/A RANTES genotype was signiﬁ-
cantly correlated with a higher grade of stenosis,
expressed as percentage of ICA occlusion (Table 3). To
conﬁrm this data the mean percentage of carotid occlu-
sion was 75.3 ± 11.4 vs 80.3 ± 11.2 (GG vs GA + AA);
p = 0.036.Table 2






Wt/Wt 99 (88) 252 (89) 0.9 (0.43–1.97) 0.78
Wt/D32 12 (11) 28 (10)
D32/D32 1 (1) 2 (1)
D32 frequency 0.06 0.05 0.9 (.045–1.86) 0.75
SDF-1
G/G 53 (47) 175 (62) 1.82(1.14–2.90) 0.0076
G/A 47 (42) 99 (35)
A/A 12 (11) 8 (3)
A frequency 0.32 0.20 1.81(1.25–2.60) 0.0007
MCP-1
A/A 65 (58) 152 (54) 1.18 (0.74–1.88) 0.45
A/G 43 (38) 104 (37)
G/G 4 (4) 26 (9)
G frequency 0.23 0.27 1.79 (0.89–1.90) 0.15
RANTES
G/G 74 (66) 196 (70) 0.85 (0.52–1.40) 0.50
G/A 32 (28) 80 (28)
A/A 6 (6) 6 (2)
A frequency 0.20 0.16 0.79 (0.52–1.21) 0.26
CCR2
Val/Val 90 (81) 211 (75)
Val/Iso 20 (18) 68 (24)
Iso/Iso 2 (1) 3 (1) 1.37 (0.78–2.48) 0.50
Iso frequency 0.19 0.13 1.25 (0.75–2.14) 0.35
Data are expressed as absolute values (genotype frequency, %). The ORs
were calculated as wild type homozygots vs mutants (heterozygots plus
homozygots).Among patients, -2518A/G MCP-1 genotype distribu-
tion showed some degree of correlation with the stenosis
percentage, G allele being more represented in more
severely aﬀected subjects, but the diﬀerence did not reach
statistical signiﬁcance (p = 0.09) (Table 3).4. Discussion
Gene polymorphisms that modify expression and/or
bioavailability of chemokines and their cellular receptors
may aﬀect leucocyte traﬃcking in inﬂammatory diseases,
including atherosclerosis [15].
In our study, the SNPs SDF-1 A, and RANTES A-403
were signiﬁcantly associated with susceptibility and clinical
course of ICA stenosis disease. The other three gene vari-
ants studied (MCP-1 G, CCR2 I, CCR5D32) did not showTable 3
Genotype of Chemokines in ICA stenosis patients according to the
severity of the stenosis
CCR5 <70 (n = 46) >70 (n = 66) OR (CI%) p
Wt/Wt 43 (93) 56 (84) 2.55 (0.6–15.2) 0.16
Wt/D32 2 (4) 10 (16)
D32/D32 1 (3) 0
D32 frequency 0.04 0.07 1.84 (0.51–8.3) 0.30
SDF-1
G/G 24 (52) 29 (44) 1.39 (0.61–3.17) 0.39
G/A 17 (37) 30 (45)
A/A 5 (11) 7 (11)
A frequency 0.29 0.39 1.20 (0.65–2.24) 0.52
MCP-1
A/A 31 (67) 34 (52) 1.94 (0.83–4.61) 0.09
A/G 13 (28) 30 (45)
G/G 2 (5) 2 (3)
G frequency 0.18 0.30 1.53 (0.76–3.15) 0.20
RANTES
G/G 36 (78) 38 (57) 2.65 (1.05–6.97) 0.022
G/A 9 (20) 23 (35)
A/A 1 (2) 5 (8)
A frequency 0.12 0.25 2.45 (1.12–5.71) 0.015
CCR2
Val/Val 36 (79) 54 (82) 0.80 (0.28–2.31) 0.64
Val/Iso 9 (19) 11 (17)
Iso/Iso 1 (2) 1 (1)
Iso frequency 0.19 0.13 0.80 (0.31–2.09) 0.61
Data are expressed as absolute values (genotype frequency, %). The ORs
were calculated as wild type homozygots vs mutants (heterozygots plus
homozygots).
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nor with its severity.
Recruitment of circulating monocytes to the arterial
intima contributes to the formation of atherosclerotic
lesions and may participate in their destabilization [4]. Leu-
kocyte emigration from blood into arterial wall tissue is
mediated by multiple adhesion molecules and chemokines,
depending on their expression patterns of chemokine recep-
tors [5].
Carriers of the A allele in the SDF-1 gene were at
increased risk of developing ICA occlusive disease com-
pared with individuals homozygous for the G. The -801A
variant of the SDF-1 gene has been associated with genetic
restriction of AIDS pathogenesis, as well as with enhanced
CD34+ progenitor cell mobilisation from bone marrow
[29,30]. Soriano et al. have shown an association between
high plasma SDF-1 levels and the SDF-1 A allele [31].
However, other studies demonstrated that SDF-1, at least
in high concentrations, may mediate anti-inﬂammatory
and matrix-stabilizing eﬀects in unstable angina.
The -403A variant of the RANTES gene resulted in
up to 8-fold increased constitutive transcriptional activ-
ity after transient transfection in human mast-cell and
T-cell lines [32]. Data in mice demonstrated that Met-
RANTES (RANTES receptor antagonist) reduced pla-
que formation and these eﬀects could be linked to a
decrease in leukocyte inﬁltration with inhibition of neo-
intima formation [11]. Recently RANTES-403A has
been associated with several inﬂammatory disease in
humans [32–34]. In atherosclerosis Simeoni et al. [35]
showed that the RANTES-403A allele was associated
with CAD independently from conventional cardiovas-
cular risk factors, Data conﬁrmed in our results that
could demonstrate a genetic component in the develop-
ment of ICA stenosis in some way linked to the more
active RANTES gene variant.
The lack of correlations between clinical signs of stroke
and the examined SNPs on RANTES, and SDF-1 gene
could actually be aﬀected by the size of the sample and
the fact that carotid surgery is indicated and eﬀective in
the prevention of cerebral ischemia. Therefore, further
investigations would be suggested.
Polymorphisms in other chemokine genes have also
been associated with atherosclerosis. The rare Val64Ile
polymorphism in the CCR2 gene was associated with
reduced coronary calciﬁcation, as well as MCP-1 G2518
homozygosity [36,37]. On the contrary Brenner et al. dem-
onstrated a A2518 association with increased IMT [38].
However, this association was not found for ICA occlusive
disease in the present study, in accordance with Tabara
et al. study that demonstrated a lack of association with
carotid intima-media thickness in Japanese [39]. These dif-
ferences could be explained by diﬀerent patients popula-
tions or the disease state. In a recently published study
we demonstrated that the CCR5D32 polymorphism can
be regarded as a risk factor for abdominal aortic aneurysm
and its tendency to rupture [40]. Others reported on theprotective eﬀect of this deletion polymorphism against pre-
mature myocardial infarction [41]. In the present study
ICA occlusive disease seems to be indiﬀerent to this
variant.
In conclusion, our results successfully try to correlate
the polymorphisms of the genes encoding for SDF-1, and
RANTES with pathogenesis and progression of ICA occlu-
sive disease. Although suggestive, these results need conﬁr-
mation in prospective cross-sectional studies.
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